Named on 10 rounds in the feed, most often at Series D+ and in Biotech.
Rounds from 2021-05-13 to 2026-07-15
ROUNDS
10
led 4, joined 6
LED ROUNDS · USD
$131.7M
across 4 rounds · 2 co-led, split evenly
CO-INVESTORS
58
most often with T. Rowe Price
Named on 10 rounds in the feed, most often at Series D+ and in Biotech.
Rounds from 2021-05-13 to 2026-07-15
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
AdvanCell AdvanCell is developing targeted alpha radiotherapies for cancer. | Series D Verified against 4 of 6 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $315M | 2026-07-15 | [ PART ] |
Leo Cancer Care Leo Cancer Care makes upright radiation therapy systems that treat cancer patients seated or standing. | Series D Verified against 1 of 3 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $65M | 2026-07-08 | [ PART ] |
Flare Therapeutics A biotech startup targeting transcription factors | Series C Verified against 5 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $85M | 2026-06-30 | [ PART ] |
Avalyn Pharma Avalyn Pharma develops inhaled therapies targeting rare respiratory diseases, specifically pulmonary fibrosis and interstitial lung diseases, for patients and their care partners. | Series D Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2025-07-23 | [ PART ] |
Kardium Kardium sells the Globe Pulsed Field System, a medical device for precise ablation and high-density mapping in healthcare. | Funding round Verified against 1 of 5 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $250M | 2025-07-02 | [ LEAD ] |
PreciseDx A digital pathology platform that uses AI to assess breast cancer risk | Funding round Developing, 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $11M | 2025-06-18 | [ LEAD ] |
PreciseDx A digital pathology platform that uses AI to assess breast cancer risk | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $20.7M | 2024-08-21 | [ LEAD ] |
Avalyn Pharma Avalyn Pharma develops inhaled therapies targeting rare respiratory diseases, specifically pulmonary fibrosis and interstitial lung diseases, for patients and their care partners. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $175M | 2023-09-27 | [ LEAD ] |
Flare Therapeutics A biotech startup targeting transcription factors | Series B Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $123M | 2023-03-22 | [ PART ] |
Flare Therapeutics A biotech startup targeting transcription factors | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $82M | 2021-05-13 | [ PART ] |